clinical practice guidelinesProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Under an Elsevier user license
open archive
Cited by (0)
Approved by the ESMO Guidelines Working Group: February 2002, last update March 2010. This publication supercedes the previously published version—Ann Oncol 2009; 20 (Suppl 4): iv76-iv78.
Conflict of interest: Prof. Horwich has reported that his institution is the inventor of the drug Abiraterone which is being investigated in prostate cancer and may lead to royalties payment to the institute; Dr Parker has reported that he is a consultant for Algeta and that he has received honoraria from Takeda, Bayer and Johnson & Johnson; Prof. Bangma and Dr Kataja have reported no conflicts of interest.
Copyright © 2010 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.